Company Overview
Propanc is currently focused on developing new cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. We have developed a formulation of anti-cancer compounds which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Our products involve or employ proenzymes, which are inactive precursors of enzymes.
Recent News
Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution Medicines’ Daraxonrasib
Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results
Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015
Stock Overview
10/09/2026 02:19 PM EDT
Investor Relations
Propanc Biopharma, Inc.
T: +61-03-9882-6723
irteam@propanc.com